Dr. Anhui Shi 石安辉
Chief Physician, Associate Professor
Department of Radiation Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Precision radiotherapy and chemotherapy for lung, esophageal, and thymic tumors. Stereotactic body radiation therapy (SBRT) for brain, lung, bone, adrenal, and liver metastases from common solid tumors.
Dr. Shi holds a PhD and serves as Chief Physician and Associate Professor. Specializing in radiation oncology, Dr. Shi focuses on precision radiotherapy and comprehensive treatment for thoracic tumors, as well as SBRT for metastases using technologies such as CyberKnife, Novalis, and TomoTherapy.
Professional roles
- Deputy Leader, Lung Cancer Group, Radiotherapy Branch, Chinese Medical Doctor Association
- Member, Youth Committee of Radiation Oncology, China Anti-Cancer Association
- Member, Radiosurgery Group, 8th Committee of Radiation Oncology, Chinese Medical Association
- Deputy Chair, Lung Cancer Youth Committee, Beijing Medical Award Foundation
Name order: in Chinese the family name comes first (Shi Anhui). Papers usually list the name as Anhui Shi or Shi A.
Selected publications
62 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- Pract Radiat Oncol, 2026 (senior author): Real-World Clinical Outcomes in Patients With Limited-Stage Small Cell Lung Cancer Who Received High-Dose Hyperfractionated Simultaneous Integrated Boost Radiation Therapy Versus Standard-Dose Radiation Therapy. PubMed 42034286
- Transl Lung Cancer Res, 2026 (senior author): Real-world analysis in patients with limited-stage small-cell lung cancer who received durvalumab after concurrent chemoradiotherapy. PubMed 42582865
- Pract Radiat Oncol, 2026 (senior author): Comparative Effectiveness and Safety of Prophylactic Cranial Irradiation Versus Magnetic Resonance Imaging Surveillance in Limited-Stage Small Cell Lung Cancer. PubMed 42425226
- Ther Adv Med Oncol, 2026 (senior author): Definitive radiotherapy provides comparable survival with lower toxicity compared with concurrent chemoradiotherapy after long-course induction chemoimmunotherapy in unresectable non-small-cell lung cancer. PubMed 42199487
- BMC Cancer, 2026 (senior author): Impact of chemotherapy dose reduction during concurrent chemoradiotherapy on survival outcomes in limited-stage small-cell lung cancer. PubMed 42163158
- Front Oncol, 2026 (senior author): Salvage definitive or hypofractionated radiotherapy for oligometastatic recurrence after durvalumab consolidation in limited-stage small-cell lung cancer: a two-case report. PubMed 42057823
- Lancet Respir Med, 2024 (senior author): Time to escalate quality assurance in small-cell lung cancer radiotherapy trials - Authors' reply. PubMed 39638534
- Front Immunol, 2024 (senior author): Bevacizumab reduces cerebral radiation necrosis due to stereotactic radiotherapy in non-small cell lung cancer patients with brain metastases: an inverse probability of treatment weighting analysis. PubMed 39257576
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion